Pacira BioSciences, Inc. · NASDAQ:PCRX
Pacira BioSciences — Technical Presentation (2024)
9 slides from Pacira BioSciences's technical presentation, 2024
Slide 1: Innovations in Genicular Outcomes Registry (iGOR): OAK Pain Outcomes
Innovations in Genicular Outcomes Registry (iGOR): Osteoarthritis of the Knee (OAK) Pain Outcomes Andrew I. Spitzer,1 Vinod Dasa,2 Adam Rivadeneyra,3 David Rogenmoser,4 Joshua Urban,5 Michael A. Mont,6 Andrew Concoff,7 Jennifer H. Lin,8 William Mihalko9 1Cedars Sinai Medical Center, Los Angeles, CA;
Slide 2: Financial Disclosures
FINANCIAL DISCLOSURES AS has given paid presentations and received research fees from DePuy and Pacira BioSciences, Inc., and received consultancy fees from DePuy, Flexion Therapeutics, Pacira BioSciences, Inc., and TraumaCad. VD has given paid presentations for BioVentus, Pacira BioSciences, Inc.,
Slide 3: Introduction
INTRODUCTION • Treatment of OAK, focused on reducing pain and improving function,1 is often long term and involves multiple treatment modalities given chronicity of disease and individual patient considerations over time (eg, comorbidities, goals)2 ‒ Although innovative nonsurgical OAK treatments (e
Slide 4: Methods: Registry and Study Design
METHODS: Registry and Study Design • The iGOR (NCT05495334) is an observational registry, with all treatment decisions made by Current Analysis patients and their providers in a shared decision- Eligibility: making manner • ≥1 month of follow-up • Unilateral OAK • Participants enrolled in iGOR compl
Slide 5: Results: Patient Demographics and Baseline Characteristics
IA-HA IA-NSAID IA-CS IA-TA-ER Cryo Total RESULTS: Patient Age, mean (SD), y (n=21) 63 (11) (n=19) 59 (10) (n=75) 60 (9) (n=15) 63 (11) (n=48) 63 (10) (N=178) P value* 61 (10) 0.14 Demographics and Sex, n (%) Female 16 (76) 16 (84) 47 (63) 12 (80) 42 (88) 133 (75) 0.03 Baseline Characteristics Race,
Slide 6: Results: Pain Severity Outcomes
RESULTS: Pain Severity Outcomes Reduction of pain from baseline was significant for most During the 3 months of follow-up after treatment, pain treatments (except IA-NSAID), with IA-TA-ER associated with the severity was reduced from baseline for all treatments (left) greatest reduction from baselin
Slide 7: Results: Functional Outcomes
RESULTS: Functional Outcomes Over the 3-month follow-up period, numerical improvements from baseline in KOOS-JR scores were observed for all treatments,* with IA-TA-ER injection associated with greatest functional improvement compared with all other IA injections Post-Treatment KOOS-JR Functional Sc
Slide 8: Results: Opioid Use Outcomes
RESULTS: Opioid Use Outcomes In this iGOR analysis including patients who received nonsurgical treatments for Opioid Use During 3 Months of Follow-up OAK, 38 patients of 178 total patients (21%) reported using opioids during the No opioid Opioid use follow-up period use 21% • 22 of 178 total patient
Slide 9: Conclusions
CONCLUSIONS 1 Early results from the iGOR, a unique, first-of-its-kind, inclusive, and comprehensive registry, exhibited the feasibility of using a registry to obtain real-world data for the comparative effectiveness of OAK treatments 2 In the current analyses, numerical improvements in pain and fun